References analysis of the Wikipedia article "Vesicular monoamine transporter" in the English version

doi.org

Eiden LE, Weihe E (January 2011). "VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse". Ann. N. Y. Acad. Sci. 1216 (1): 86–98. Bibcode:2011NYASA1216...86E. doi:10.1111/j.1749-6632.2010.05906.x. PMC 4183197. PMID 21272013. VMAT2 is the CNS vesicular transporter for not only the biogenic amines DA, NE, EPI, 5-HT, and HIS, but likely also for the trace amines TYR, PEA, and thyronamine (THYR) ... [Trace aminergic] neurons in mammalian CNS would be identifiable as neurons expressing VMAT2 for storage, and the biosynthetic enzyme aromatic amino acid decarboxylase (AADC).

Eiden L., Schäfer M. H., et al. (2004). "The vesicular amine transporter family (SLC18) amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine". Pflügers Archiv. 447 (5): 636–640. doi:10.1007/s00424-003-1100-5. PMID 12827358. S2CID 20764857.

Wimalasena K (2011). "Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry". Med Res Rev. 31 (4): 483–519. doi:10.1002/med.20187. PMC 3019297. PMID 20135628.

Henry J. P., Botton D., et al. (1994). "Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules". J Exp Biol. 196: 251–62. doi:10.1242/jeb.196.1.251. PMID 7823026.

Fei H., Grygoruk A., et al. (2008). "Trafficking of vesicular neurotransmitter transporters". Traffic. 9 (9): 1425–36. doi:10.1111/j.1600-0854.2008.00771.x. PMC 2897747. PMID 18507811.

Brunk I., Höltje B., et al. (2006). Regulation of vesicular monoamine and glutamate transporters by vesicle-associated trimeric G-proteins: new jobs for long-known signal transduction molecules. Handbook of Experimental Pharmacology. Vol. 175. pp. 305–25. doi:10.1007/3-540-29784-7_15. ISBN 978-3-540-29783-3. PMID 16722242.

Höltje M., Winter S., et al. (May 2003). "The vesicular monoamine content regulates VMAT2 activity through Galphaq in mouse platelets. Evidence for autoregulation of vesicular transmitter uptake". Journal of Biological Chemistry. 278 (18): 15850–15858. doi:10.1074/jbc.M212816200. PMID 12604601.

Wimalasena K (2010). "Vesicular monoamine transporters: structure-function, pharmacology and medicinal chemistry". Medicinal Research Reviews. 31 (4): 483–19. doi:10.1002/med.20187. PMC 3019297. PMID 20135628.

Liu Y, Peter D, Rogahani A, Schuldiner S, Prive GG, Eisenberg D, Brecha N, Edwards RH (1992). "A cDNA that suppresses MPP1 toxicity encodes a vesicular amine transporter". Cell. 70 (4): 539–551. doi:10.1016/0092-8674(92)90425-c. PMID 1505023. S2CID 6225156.

Chaudhry FA, Edwards RH, Fonnum F (2007). "Vesicular neurotransmitter transporters as targets for endogenous and exogenous toxic substances". Annu. Rev. Pharmacol. Toxicol. 48: 277–301. doi:10.1146/annurev.pharmtox.46.120604.141146. PMID 17883368.

Merickel A, Kaback HR, Edwards RH (1997). "Charged residues in transmembrane domains II and XI of a vesicular monoamine transporter form a charge pair that promotes high affinity substrate recognition". J. Biol. Chem. 272 (9): 5403–5408. doi:10.1074/jbc.272.9.5403. PMID 9038139.

Steiner-Mordoch S, Shirvan A, Schuldiner S (1996). "Modification of the pH profile and tetrabenazine sensitivity of rat VMAT1 by replacement of aspartate 404 with glutamate". J. Biol. Chem. 271 (22): 13048–13054. doi:10.1074/jbc.271.22.13048. PMID 8662678.

Peter D, et al. (1994). "The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors". J Biol Chem. 269 (10): 7231–7237. doi:10.1016/S0021-9258(17)37272-1. PMID 8125935.

Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E (1996). "Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter". Proc. Natl. Acad. Sci. USA. 93 (10): 5166–5171. Bibcode:1996PNAS...93.5166E. doi:10.1073/pnas.93.10.5166. PMC 39426. PMID 8643547.

Miller GW, Gainetdinov RR, Levey AI, Caron MG (1999). "Dopamine transporters and neuronal injury". Trends in Pharmacological Sciences. 20 (10): 424–429. doi:10.1016/S0165-6147(99)01379-6. PMID 10498956.

Fleckenstein AE, Volz TJ, Hanson GR (2009). "Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: Neurotoxic and therapeutic implications". Neuropharmacology. 56 (Suppl 1): 133–138. doi:10.1016/j.neuropharm.2008.07.002. PMC 2634813. PMID 18662707.

Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR (2007). "New insights into the mechanism of action of amphetamines". Annu Rev Pharmacol Toxicol. 47: 681–98. doi:10.1146/annurev.pharmtox.47.120505.105140. PMID 17209801.

Sulzer D, Sonders MS, Poulsen NW, Galli A (April 2005). "Mechanisms of neurotransmitter release by amphetamines: a review". Prog. Neurobiol. 75 (6): 406–433. doi:10.1016/j.pneurobio.2005.04.003. PMID 15955613. S2CID 2359509. They also demonstrated competition for binding between METH and reserpine, suggesting they might bind to the same site on VMAT. George Uhl's laboratory similarly reported that AMPH displaced the VMAT2 blocker tetrabenazine (Gonzalez et al., 1994)....tetrabenazine and reserpine are thought to bind to different sites on VMAT (Schuldiner et al., 1993a)

Darchen F, Scherman D, Henry JP (1989). "Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter". Biochemistry. 28 (4): 1692–1697. doi:10.1021/bi00430a040. PMID 2719928.

Liu Y, Edwards RH (1997). "The role of vesicular transport proteins in synaptic transmission and neural degeneration". Annu. Rev. Neurosci. 20: 125–156. doi:10.1146/annurev.neuro.20.1.125. PMID 9056710.

Lohoff FW, Weller AE, Bloch PJ, Buono RJ, Doyle GA, Ferraro TN, Berrettini WH (2008). "Association between Polymorphisms in the Vesicular Monoamine Transporter 1 Gene (VMAT1/SLC18A1) on Chromosome 8p and Schizophrenia". Neuropsychobiology. 57 (1–2): 55–60. doi:10.1159/000129668. ISSN 0302-282X. PMID 18451639. S2CID 39523023.

Tillinger A, Sollas A, Serova LI, Kvetnansky R, Sabban EL (2010). "Vesicular monoamine transporters (VMATs) in adrenal chromaffin cells: stress-triggered induction of VMAT2 and expression in epinephrine synthesizing cells". Cell Mol Neurobiol. 30 (8): 1459–1465. doi:10.1007/s10571-010-9575-z. PMID 21046458. S2CID 21852075.

Okamura N, Villemagne VL, Drago J, Pejoska S, Dhamija RK, Mulligan RS, Ellis JR, Ackermann U, O'Keefe G, Jones G, Kung HF, Pontecorvo MJ, Skovronsky D, Rowe CC (2010). "In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133". J. Nucl. Med. 51 (2): 223–228. doi:10.2967/jnumed.109.070094. PMID 20080893.

Villemagne VL, Okamura N, Pejoska S, Drago J, Mulligan RS, Chetelat G, Ackermann U, O'Keefe G, Jones G, Gong S, Tochon-Danguy H, Kung HF, Masters CL, Skovronsky DM, Rowe CC (2011). "In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease". Arch. Neurol. 68 (7): 905–912. doi:10.1001/archneurol.2011.142. PMID 21747030.

Salin A, Savli M, Lanzenberger R (2011). "Serotonin and molecular neuroimaging in humans using PET". Amino Acids. 42 (6): 2039–57. doi:10.1007/s00726-011-1078-9. PMID 21947614. S2CID 14118396.

Miller GW, Gainetdinov RR, Levey AI, Caron MG (1999). "Dopamine transporters and neuronal injury". TiPS. 20 (10): 425. doi:10.1016/s0165-6147(99)01379-6. PMID 10498956.

Glatt CE, Wahner AD, White DJ, Ruiz-Linares A, Ritz B (2006). "Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women". Hum. Mol. Genet. 15 (2): 299–305. doi:10.1093/hmg/ddi445. PMC 3643966. PMID 16339215.

Schwartz K, Yadid G, Weizman A, Rehavi M (2003). "Decreased limbic vesicular monoamine transporter 2 in a genetic rat model of depression". Brain Res. 965 (1–2): 174–179. doi:10.1016/s0006-8993(02)04167-7. PMID 12591135. S2CID 26761996.

Lawal HO, Krantz DE (2013). "SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine". Molecular Aspects of Medicine. 34 (2–3): 360–372. doi:10.1016/j.mam.2012.07.005. PMC 3727660. PMID 23506877.

harvard.edu

ui.adsabs.harvard.edu

nih.gov

pubmed.ncbi.nlm.nih.gov

Fei H., Grygoruk A., et al. (2008). "Trafficking of vesicular neurotransmitter transporters". Traffic. 9 (9): 1425–36. doi:10.1111/j.1600-0854.2008.00771.x. PMC 2897747. PMID 18507811.

Salin A, Savli M, Lanzenberger R (2011). "Serotonin and molecular neuroimaging in humans using PET". Amino Acids. 42 (6): 2039–57. doi:10.1007/s00726-011-1078-9. PMID 21947614. S2CID 14118396.

Miller GW, Gainetdinov RR, Levey AI, Caron MG (1999). "Dopamine transporters and neuronal injury". TiPS. 20 (10): 425. doi:10.1016/s0165-6147(99)01379-6. PMID 10498956.

ncbi.nlm.nih.gov

semanticscholar.org

api.semanticscholar.org

Salin A, Savli M, Lanzenberger R (2011). "Serotonin and molecular neuroimaging in humans using PET". Amino Acids. 42 (6): 2039–57. doi:10.1007/s00726-011-1078-9. PMID 21947614. S2CID 14118396.

worldcat.org

search.worldcat.org

Vesicular monoamine transporter (English Wikipedia)

acs.org

pubs.acs.org

doi.org

harvard.edu

ui.adsabs.harvard.edu

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

semanticscholar.org

api.semanticscholar.org

worldcat.org

search.worldcat.org

zenodo.org